Ovid Therapeutics Secures Major Funding & Announces Positive Drug Trial Results

Ovid Therapeutics secured up to $175 million in financing to fund its clinical pipeline into 2028. The company also reported positive Phase 1 results for OV329, a next-generation epilepsy drug candidate.